Effect of Diltiazem, a Moderate CYP3A Inhibitor, on the Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein Inhibitor, in Healthy Subjects

被引：15

作者：

Garg, Amit ^{[1
]}

Maes, Andrea ^{[1
]}

Corr, Christy ^{[1
]}

Jin, Bo ^{[1
]}

Wadhwa, Tarun ^{[1
]}

Handa, Nikhil ^{[1
]}

Van Dyck, Kristien ^{[1
]}

De Lepeleire, Inge ^{[1
]}

Shah, Jinesh ^{[2
]}

Wagner, John A. ^{[1
]}

Krishna, Rajesh ^{[1
]}

机构：

[1] Merck & Co Inc, Whitehouse Stn, NJ USA

[2] Veeda Clin Res, Ahmadabad, Gujarat, India

来源：

JOURNAL OF CLINICAL PHARMACOLOGY | 2011年 / 51卷 / 03期

关键词：

Cholesteryl ester transfer protein inhibition; CYP3A; diltiazem; CETP INHIBITOR; DRUG-INTERACTION; BLOOD-PRESSURE; 3A ACTIVITY; MIDAZOLAM;

D O I：

10.1177/0091270010368676

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

页码：436 / 439

页数：4

共 50 条

[41] Effect of CYP3A inducer/inhibitor on pharmacokinetics of five alkaloids in Evodiae Fructus
Zhang, Wei
Guo, Jingyan
Wang, Dongmei
Ren, Shumeng
Hua, Huiming
Morikawa, Toshio
Pan, Yingni
Liu, Xiaoqiu
CHEMICO-BIOLOGICAL INTERACTIONS, 2020, 327
[42] Effect of Food on the Pharmacokinetics of 2 Formulations of DRL-17822, a Novel Selective Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Males
Kruithof, Annelieke C.
Kumar, Rajinder
Stevens, Jasper
de Kam, Marieke L.
Gautam, Anirudh
Alikunju, Shanavas
Padhi, Bijay K.
Kulkarni, Swati
Raghuvanshi, Rajeev S.
Gandhi, Rajesh
Burggraaf, Jacobus
Kamerling, Ingrid M. C.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (08): : 1042 - 1052
[43] Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of Multiple-Doses of DRL-17822, a Potent Cholesteryl Ester Transfer Protein Inhibitor in Healthy Male Subjects
Dasari, Mallikarjuna Rao
Bapat, Abhijit
Vittal, Shivva
Tippana, Mangapathiraju
Hasham, Sumera
Sai, Sesha M.
Alikunju, Shanavas
Sadashivam, Vasu
Allenby, Kent
Kumar, Rajinder
CIRCULATION, 2010, 122 (21)
[44] Cholesteryl ester transfer protein inhibitor BMS-795311
Qiao, Jennifer
Wang, Tammy
Chen, Alice Ye
Taylor, David
Yang, Richard
Sleph, Paul
Li, Julia
Li, Danshi
Chang, Ming
Chen, Xue-Qing
Xu, Carrie
Li, Jianqing
Smith, Daniel
Wu, Dauh-Rurng
Leith, Leslie
Harikrishnan, Lalgudi
Kamau, Muthoni
Rampulla, Richard
Miller, Michael
Bilder, Donna
Lawrence, R. Michael
Poss, Michael
Levesque, Paul
Huang, Christine
Adam, Leonard
Wexler, Ruth
Finlay, Heather
Salvati, Mark
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249
[45] EFFECT OF DILTIAZEM, A MODERATE CYP3A4 INHIBITOR, ON THE PHARMACOKINETIC PARAMETERS OF TAMSULOSIN
Lee, Y.
Byeon, J. Y.
Kim, Y. H.
Kim, S. H.
Lee, H. J.
Lee, Y. J.
CLINICAL THERAPEUTICS, 2015, 37 (08) : E61 - E62
[46] A depsipeptide fungal metabolite inhibitor of cholesteryl ester transfer protein
Hegde, VR
Dai, P
Patel, M
Das, PR
Wang, S
Puar, MS
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (11) : 1277 - 1280
[47] Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol
Brousseau, ME
Schaefer, EJ
Wolfe, ML
Bloedon, LT
Digenio, AG
Clark, RW
Mancuso, JP
Rader, DJ
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15): : 1505 - 1515
[48] A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits
Okamoto, H
Yonemori, F
Wakitani, K
Minowa, T
Maeda, K
Shinkai, H
NATURE, 2000, 406 (6792) : 203 - 207
[49] Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects
Fukumura, Kazuya
Kawaguchi, Nao
Ishibashi, Toru
Kubota, Ryuji
Tada, Yukio
Ogura, Eriko
CLINICAL DRUG INVESTIGATION, 2020, 40 (06) : 529 - 540
[50] Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects
Kazuya Fukumura
Nao Kawaguchi
Toru Ishibashi
Ryuji Kubota
Yukio Tada
Eriko Ogura
Clinical Drug Investigation, 2020, 40 : 529 - 540

← 1 2 3 4 5 →